ReadoutIn window
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair — ETOPOSIDE - Usual
Phase 3 primary completion: Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms.
- Date
- Nov 2026
- Type
- Readout
- Indication
- Small Cell Lung Cancer